The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. (2020)
Attributed to:
King’s College London Confidence in Concept
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00259-019-04643-7
PubMed Identifier: 31872280
Publication URI: http://europepmc.org/abstract/MED/31872280
Type: Journal Article/Review
Volume: 47
Parent Publication: European journal of nuclear medicine and molecular imaging
Issue: 3
ISSN: 1619-7070